Cited by 1,690Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancerChromatin Remodeling and Cancer

The DOI matches its Crossref record; 115 of the 122 references it cites were found in a registry or an index.

The RB and p53 pathways in cancer

Open access

Sherr, Charles J, McCormick, Frank·2002·Cancer Cell

Open this paper in CoChat — free account Open PDF

Abstract

The life history of cancer cells encompasses a series of genetic missteps in which normal cells are progressively transformed into tumor cells that invade surrounding tissues and become malignant. Most prominent among the regulators disrupted in cancer cells are two tumor suppressors, the retinoblastoma protein (RB) and the p53 transcription factor. Here, we discuss interconnecting signaling pathways controlled by RB and p53, attempting to explain their potentially universal involvement in the etiology of cancer. Pinpointing the various ways by which the functions of RB and p53 are subverted in individual tumors should provide a rational basis for developing more refined tumor-specific therapies.

Integrity signals

Registry

Crossref · 10.1016/s1535-6108(02)00102-2

Cites

115 of 115 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The hallmarks of cancer
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Self-citation
Cancer Cell Cycles
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
Self-citation
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“By inducing Arf and Ink4a in primary rodent fibroblasts, oncogenic Ras expression leads to growth arrest and premature senescence (Serrano et al., 1997; Ferbeyre et al., 2002).”
Background
The regulation of E2F by pRB-family proteins.
Dyson, N. (1998) · Genes & Development · doi:10.1101/gad.12.15.2245 · Cited by 2,317
Safety and antitumor activity of recombinant soluble Apo2 ligand
Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6926 · Cited by 2,213
Untitled work
Johnstone (2002) · doi:10.1016/s0092-8674(02)00625-6 · Cited by 1,876
The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice
Adams, J. M., Harris, A. W., Pinkert, C. A., Corcoran, L. M., Alexander, W. S., Cory, S., Palmiter, R. D., & Brinster, R. L. (1985) · Nature · doi:10.1038/318533a0 · Cited by 1,779
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585
The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus
Jacobs, J. J. L., Kieboom, K., Marino, S., DePinho, R. A., & van Lohuizen, M. (1999) · Nature · doi:10.1038/16476 · Cited by 1,580
Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19
Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., & Sherr, C. J. (1997) · Cell · doi:10.1016/s0092-8674(00)80452-3 · Cited by 1,566
Self-citation
Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest
Ouelle, D. E., Zindy, F., Ashmun, R. A., & Sherr, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90214-7 · Cited by 1,485
Self-citation
New functional activities for the p21 family of CDK inhibitors.
LaBaer, J., Garrett, M. D., Stevenson, L. F., Slingerland, J. M., Sandhu, C., Chou, H. S., Fattaey, A., & Harlow, E. (1997) · Genes & Development · doi:10.1101/gad.11.7.847 · Cited by 1,402
The complexity of p53 modulation: emerging patterns from divergent signalsPreprint
Giaccia, A. J., & Kastan, M. B. (1998) · Genes & Development · doi:10.1101/gad.12.19.2973 · Cited by 1,315
A Chemical Inhibitor of p53 That Protects Mice from the Side Effects of Cancer Therapy
Komarov, P. G., Komarova, E. A., Kondratov, R. V., Christov-Tselkov, K., Coon, J. S., Chernov, M. V., & Gudkov, A. V. (1999) · Science · doi:10.1126/science.285.5434.1733 · Cited by 1,270
Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization
Zindy, F., Eischen, C. M., Randle, D. H., Kamijo, T., Cleveland, J. L., Sherr, C. J., & Roussel, M. F. (1998) · Genes & Development · doi:10.1101/gad.12.15.2424 · Cited by 1,245
Self-citation
A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus
Mayo, L. D., & Donner, D. B. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.181181198 · Cited by 1,230
Sibling rivalry in the E2F family
Trimarchi, J. M., & Lees, J. A. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm714 · Cited by 1,158
The Rb/E2F pathway: expanding roles and emerging paradigms
Harbour, J. W., & Dean, D. C. (2000) · Genes & Development · doi:10.1101/gad.813200 · Cited by 1,153
The p21Cip1 and p27Kip1 CDK ‘inhibitors’ are essential activators of cyclin D‐dependent kinases in murine fibroblasts
Cheng, M., Olivier, P., Diehl, J. A., Fero, M., Roussel, M. F., Roberts, J. M., & Sherr, C. J. (1999) · The EMBO Journal · doi:10.1093/emboj/18.6.1571 · Cited by 1,142 · cited 3×
“, and Sherr, C.J. (1997). Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF.”
BackgroundSelf-citation
A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
Khuri, F. R., Nemunaitis, J. J., Ganly, I., Arseneau, J. C., Tannock, I. F., Romel, L., Gore, M. E., Ironside, J. A. D., MacDougall, R. H., Heise, C. C., et al. (2000) · Nature Medicine · doi:10.1038/78638 · Cited by 1,099
Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARFPreprint
Jacobs, J. J. L., Scheijen, B., Voncken, J. W., Kieboom, K., Berns, A. J. M., & van Lohuizen, M. (1999) · Genes & Development · doi:10.1101/gad.13.20.2678 · Cited by 1,069
A Senescence Program Controlled by p53 and p16INK4a Contributes to the Outcome of Cancer Therapy
Schmitt, C. A., Fridman, J. S., Yang, M., Lee, S., Baranov, E., Hoffman, R. M., & Lowe, S. W. (2002) · Cell · doi:10.1016/s0092-8674(02)00734-1 · Cited by 1,050
Cyclin D1 provides a link between development and oncogenesis in the retina and breast
Sicinski, P., Donaher, J. L., Parker, S. B., Li, T., Fazeli, A., Gardner, H., Haslam, S. Z., Bronson, R. T., Elledge, S. J., & Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90034-9 · Cited by 1,021
Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts
Alcorta, D. A., Xiong, Y., Phelps, D., Hannon, G., Beach, D., & Barrett, J. C. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.13742 · Cited by 1,008 · cited 1×
“A progressive increase in p16Ink4a levels as such cells are serially passaged correlates with their diminishing proliferative capacity, arguing for a role for p16Ink4a in cellular senescence (Alcorta et al., 1996; Hara et al., 1996; Zindy et al., 1997).”
Background
The INK4a/ARF network in tumour suppression
Sherr, C. J. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35096061 · Cited by 1,001
Self-citation
Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice
Wang, T. C., Cardiff, R. D., Zukerberg, L. R., Lees, E. M., Arnold, A., & Schmidt, E. V. (1994) · Nature · doi:10.1038/369669a0 · Cited by 964
Modelling the molecular circuitry of cancer
Hahn, W. C., & Weinberg, R. A. (2002) · Nature reviews. Cancer · doi:10.1038/nrc795 · Cited by 953
Expression of transcription factor E2F1 induces quiescent cells to enter S phase
Johnson, D. G., Schwarz, J. K., Cress, W. D., & Nevins, J. R. (1993) · Nature · doi:10.1038/365349a0 · Cited by 943
The Rb/E2F pathway and cancer
Nevins, J. R. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.7.699 · Cited by 939
Specific protection against breast cancers by cyclin D1 ablation
Yu, Q., Geng, Y., & Sicinski, P. (2001) · Nature · doi:10.1038/35082500 · Cited by 934
p14ARF links the tumour suppressors RB and p53
Bates, S., Phillips, A. C., Clark, P. A., Stott, F., Peters, G., Ludwig, R. L., & Vousden, K. H. (1998) · Nature · doi:10.1038/25867 · Cited by 918
The p16INK4a/CDKN2A tumor suppressor and its relatives
Ruas, M., & Peters, G. (1998) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(98)00017-1 · Cited by 911
Cyclin E-CDK2 is a regulator of p27Kip1.Preprint
Sheaff, R. J., Groudine, M. T., Gordon, M., Roberts, J., & Clurman, B. E. (1997) · Genes & Development · doi:10.1101/gad.11.11.1464 · Cited by 910
Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients
Porter, P. L., Malone, K. E., Heagerty, P. J., Alexander, G. M., Gatti, L., Firpo, E. J., Daling, J. R., & Roberts, J. M. (1997) · Nature Medicine · doi:10.1038/nm0297-222 · Cited by 901
Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus
Kamb, A., Shattuck-Eidens, D. M., Eeles, R. A., Liu, Q., Gruis, N. A., Ding, W., Hussey, C. E., Tran, T., Miki, Y., Weaver-Feldhaus, J., et al. (1994) · Nature Genetics · doi:10.1038/ng0994-22 · Cited by 855
Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis
Sharpless, N. E., Bardeesy, N., Lee, K.-H., Carrasco, D., Castrillon, D. H., Aguirre, A. J., Wu, E. A., Horner, J. W., & DePinho, R. A. (2001) · Nature · doi:10.1038/35092592 · Cited by 848
Decreased levels of the cell-cycle inhibitor p27Kip1 protein: Prognostic implications in primary breast cancer
Catzavelos, C., Bhattacharya, N., Ung, Y., Wilson, J. A., Roncari, L., Sandhu, C., Shaw, P. H., Yeger, H., Morava‐Protzner, I., Kapusta, L. R., et al. (1997) · Nature Medicine · doi:10.1038/nm0297-227 · Cited by 824
Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis
Eischen, C. M., Weber, J. D., Roussel, M. F., Sherr, C. J., & Cleveland, J. L. (1999) · Genes & Development · doi:10.1101/gad.13.20.2658 · Cited by 819
Self-citation
Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases
Hoessel, R., Leclerc, S., Endicott, J., Nobel, M. E. M., Lawrie, A. M., Tunnah, P., Leost, M., Damiens, E., Marie, D., Marko, D., et al. (1999) · Nature Cell Biology · doi:10.1038/9035 · Cited by 816
Exploiting Chemical Libraries, Structure, and Genomics in the Search for Kinase Inhibitors
Gray, N. S., Wodicka, L. M., Thunnissen, A. M. W. H., Norman, T., Kwon, S., Espinoza, F. H., Morgan, D. O., Barnes, G., Leclerc, S., Meijer, L., et al. (1998) · Science · doi:10.1126/science.281.5376.533 · Cited by 808
Pharmacological Rescue of Mutant p53 Conformation and Function
Foster, B. A., Coffey, H. A., Morin, M. J., & Rastinejad, F. (1999) · Science · doi:10.1126/science.286.5449.2507 · Cited by 802
Cyclin D-dependent kinases, INK4 inhibitors and cancer
Ortega, S., Malumbres, M., & Barbacid, M. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00037-9 · Cited by 790
A Complex with Chromatin Modifiers That Occupies E2F- and Myc-Responsive Genes in G 0 Cells
Ogawa, H., Ishiguro, K., Gaubatz, S., Livingston, D. M., & Nakatani, Y. (2002) · Science · doi:10.1126/science.1069861 · Cited by 785
A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo
Fueyo-Margareto, J., Gomez‐Manzano, C., Alemany, R., Lee, P. S. Y., McDonnell, T. J., Mitlianga, P. G., Shi, Y.-X., Levin, V. A., Yung, W. K. A., & Kyritsis, A. P. (2000) · Oncogene · doi:10.1038/sj.onc.1203251 · Cited by 764
Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis.
Qin, X. Q., Livingston, D. M., Kaelin, W. G., & Adams, P. D. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.23.10918 · Cited by 753
Mechanisms of cyclin-dependent kinase regulation: structures of cdks, their cyclin activators, and cip and INK4 inhibitors
Pavletich, N. P. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.2640 · Cited by 746
Cellular Senescence
Sherr, C. J., & DePinho, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)00046-5 · Cited by 745
Self-citation
Regulation of p16 CDKN2 Expression and Its Implications for Cell Immortalization and Senescence
Hara, E., Smith, R., Parry, D., Tahara, H., Stone, S., & Peters, G. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.3.859 · Cited by 733
Distinct roles for E2F proteins in cell growth control and apoptosis
DeGregori, J. V., Leone, G. W., Miron, A., Jakoi, L., & Nevins, J. R. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.14.7245 · Cited by 704
Mice lacking cyclin D1 are small and show defects in eye and mammary gland development.
Fantl, V, Stamp, G., Andrews, A., Rosewell, I., & Dickson, C. (1995) · Genes & Development · doi:10.1101/gad.9.19.2364 · Cited by 691
Phosphorylation‐dependent degradation of the cyclin‐dependent kinase inhibitor p27Kip1
Vlach, J., Hennecke, S., & Amati, B. B. (1997) · The EMBO Journal · doi:10.1093/emboj/16.17.5334 · Cited by 680
E1A signaling to p53 involves the p19ARFtumor suppressorPreprint
de Stanchina, E., McCurrach, M. E., Zindy, F., Shieh, S.-Y., Ferbeyre, G., Samuelson, A. V., Prives, C. L., Roussel, M. F., Sherr, C. J., & Lowe, S. W. (1998) · Genes & Development · doi:10.1101/gad.12.15.2434 · Cited by 611
Self-citation
Targeted disruption of the three Rb-related genes leads to loss of G 1 control and immortalization
Sage, J., Mulligan, G. J., Attardi, L. D., Miller, A., Chen, S., Williams, B., Theodorou, E., & Jacks, T. (2000) · Genes & Development · doi:10.1101/gad.843200 · Cited by 582
Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging
Zindy, F., Quelle, D. E., Roussel, M. F., & Sherr, C. J. (1997) · Oncogene · doi:10.1038/sj.onc.1201178 · Cited by 574
Self-citation
Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice
Krimpenfort, P., Quon, K. C., Mooi, W. J., Loonstra, A., & Berns, A. (2001) · Nature · doi:10.1038/35092584 · Cited by 568 · cited 3×
“Yet, mice lacking p16Ink4a, in particular, are tumor prone and develop a wide spectrum of cancers, particularly after exposure to chemical carcinogens or X-rays (Serrano et al., 1996; Krimpenfort et al., 2001; Sharpless et al., 2001).”
Background
Deregulated Expression of E2F-1 Induces S-Phase Entry and Leads to Apoptosis
Shan, B., & Lee, W. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.12.8166 · Cited by 529
twist is a potential oncogene that inhibits apoptosis
Maestro, R., Tos, A. P. D., Hamamori, Y., Krasnokutsky, S., Sartorelli, V., Kedes, L., Doglioni, C., Beach, D. H., & Hannon, G. J. (1999) · Genes & Development · doi:10.1101/gad.13.17.2207 · Cited by 516
Cyclin D1 protein expression and function in human breast cancer
Bártková, J., Lukas, J., Müller, H., Lützhøt, D., Strauss, M., & Bártek, J. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910570311 · Cited by 509
Phase II Trial of Intratumoral Administration of ONYX-015, a Replication-Selective Adenovirus, in Patients With Refractory Head and Neck Cancer
Nemunaitis, J. J., Khuri, F. R., Ganly, I., Arseneau, J. C., Posner, M. R., Vokes, E. E., Kuhn, J. A., McCarty, T. M., Landers, S., Blackburn, A., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.289 · Cited by 470
INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53
Schmitt, C. A., McCurrach, M. E., de Stanchina, E., Wallace-Brodeur, R. R., & Lowe, S. W. (1999) · Genes & Development · doi:10.1101/gad.13.20.2670 · Cited by 458
p53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts.
Harvey, D. M., & Levine, A. J. (1991) · Genes & Development · doi:10.1101/gad.5.12b.2375 · Cited by 453
Putative telomere-independent mechanisms of replicative aging reflect inadequate growth conditions
Ramirez, R. D., Morales, C. P., Herbert, B.-S., Rohde, J. M., Passons, C., Shay, J. W., & Wright, W. E. (2001) · Genes & Development · doi:10.1101/gad.859201 · Cited by 444 · cited 1×
“Stress stemming from a nonphysiologic cell culture environment generates signals that activate p16Ink4a synthesis (Sherr and DePinho, 2000), but its induction can be retarded, or even eliminated, by changing conditions in which primary cells are grown (Ramirez et al., 2001).”
Background
Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation.
Lin, W.-C., Lin, F., & Nevins, J. R. (2001) · PubMed Central · Cited by 440
Ablation of the Retinoblastoma gene family deregulates G1 control causing immortalization and increased cell turnover under growth-restricting conditions
Dannenberg, J.-H., van Rossum, A., Schuijff, L., & te Riele, H. (2000) · Genes & Development · doi:10.1101/gad.847700 · Cited by 413
Cooperative effects of INK4a and ras in melanoma susceptibility in vivoPreprint
Chin, L., Pomerantz, J. H., Polsky, D., Jacobson, M., Cohen, C., Cordon‐Cardo, C., Horner, J. W., & DePinho, R. A. (1997) · Genes & Development · doi:10.1101/gad.11.21.2822 · Cited by 407
The retinoblastoma gene family in differentiation and development
Lipinski, M. M., & Jacks, T. (1999) · Oncogene · doi:10.1038/sj.onc.1203244 · Cited by 404
Telomere dynamics in cancer progression and prevention: fundamental differences in human and mouse telomere biology
Wright, W. E., & Shay, J. W. (2000) · Nature Medicine · doi:10.1038/78592 · Cited by 398
Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19ARF) and is amplified in a subset of human breast cancers
Jacobs, J. J. L., Keblusek, P., Robanus-Maandag, E., Kristel, P., Lingbeek, M., Nederlof, P. M., van Welsem, T., van de Vijver, M. J., Koh, E. Y., Daley, G. Q., et al. (2000) · Nature Genetics · doi:10.1038/81583 · Cited by 368
Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo
Böttger, A., Böttger, V., Sparks, A., Liu, W.-L., Howard, S. F., & Lane, D. P. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00374-5 · Cited by 363
The Retinoblastoma Protein Acts as a Transcriptional Coactivator Required for Osteogenic Differentiation
Thomas, D. M., Carty, S. A., Piscopo, D. M., Lee, J.-S., Wang, W.-F., Forrester, W. C., & Hinds, P. W. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00327-6 · Cited by 361
Opposing Effects of Ras on p53
Ries, S., Biederer, C., Woods, D., Shifman, O., Shirasawa, S., Sasazuki, T., McMahon, M., Oren, M., & McCormick, F. (2000) · Cell · doi:10.1016/s0092-8674(00)00123-9 · Cited by 357
Self-citation
Cancer gene therapy: fringe or cutting edge?
McCormick, F. P. (2001) · Nature reviews. Cancer · doi:10.1038/35101008 · Cited by 345
Self-citation
Stable binding to E2F is not required for the retinoblastoma protein to activate transcription, promote differentiation, and suppress tumor cell growth
Sellers, W. R., Novitch, B. G., Miyake, S., Heith, A., Otterson, G. A., Kaye, F. J., Lassar, A. B., & Kaelin, W. G. (1998) · Genes & Development · doi:10.1101/gad.12.1.95 · Cited by 343
Untitled work
(1999) · PubMed · Cited by 338
Self-citation
The INK4 family of cell cycle inhibitors in cancer
Roussel, M. F. (1999) · Oncogene · doi:10.1038/sj.onc.1202998 · Cited by 331
Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists
Chen, Y.-N. P., Sharma, S. K., Ramsey, T. M., Jiang, L., Martin, M. S., Baker, K., Adams, P. D., Bair, K. W., & Kaelin, W. G. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4325 · Cited by 315
Oncogenic ras and p53 Cooperate To Induce Cellular Senescence
Ferbeyre, G., de Stanchina, E., Lin, A. W., Querido, E., McCurrach, M. E., Hannon, G. J., & Lowe, S. W. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.10.3497-3508.2002 · Cited by 290
E2F mediates cell cycle-dependent transcriptional repression in vivo by recruitment of an HDAC1/mSin3B corepressor complex
Rayman, J. B., Takahashi, Y., Indjeian, V. B., Dannenberg, J.-H., Catchpole, S., Watson, R. J., te Riele, H., & Dynlacht, B. D. (2002) · Genes & Development · doi:10.1101/gad.969202 · Cited by 288
Differential interaction of the cyclin-dependent kinase (Cdk) inhibitor p27Kip1 with cyclin A-Cdk2 and cyclin D2-Cdk4
Blain, S. W., Montalvo, E., & Massagué, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.41.25863 · Cited by 279
Role of the retinoblastoma protein in the pathogenesis of human cancer.
Sellers, W. R., & Kaelin, W. G. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.11.3301 · Cited by 256
Telomere dysfunction provokes regional amplification and deletion in cancer genomes
O'Hagan, R. C., Chang, S., Maser, R. S., Mohan, R., Artandi, S. E., Chin, L., & DePinho, R. A. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00094-6 · Cited by 246
STI571 (Gleevec™) as a paradigm for cancer therapy
Druker, B. J. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02305-5 · Cited by 244
Formation of p27-CDK complexes during the human mitotic cell cycle.
Soos, T. J., Kiyokawa, H., Yan, J. S., Rubin, M. S., Giordano, A., DeBlasio, A., Bottega, S., Wong, B., Mendelsohn, J. M., & Koff, A. (1996) · PubMed · Cited by 238
Tumor-Specific, Replication-Competent Adenovirus Vectors Overexpressing the Adenovirus Death Protein
Doronin, K., Tóth, K., Kuppuswamy, M. N., Ward, P. A., Tollefson, A. E., & Wold, W. S. M. (2000) · Journal of Virology · doi:10.1128/jvi.74.13.6147-6155.2000 · Cited by 206
Murine fibroblasts lacking p21 undergo senescence and are resistant to transformation by oncogenic Ras.
Pantoja, C., & Serrano, M. (1999) · Oncogene · doi:10.1038/sj.onc.1202880 · Cited by 201 · cited 1×
“However, cells lacking Cip1 are not immortal and undergo efficient p19Arf-induced arrest (Pantoja and Serrano, 1999; Modestou et al. 2001).”
Background
p21Cip1 Promotes Cyclin D1 Nuclear Accumulation via Direct Inhibition of Nuclear Export
Alt, J. R., Gladden, A. B., & Diehl, J. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108867200 · Cited by 199
Mdm2: The Ups and Downs
Juven‐Gershon, T., & Oren, M. (1999) · Molecular Medicine · doi:10.1007/bf03402141 · Cited by 193
Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents
Johnson, L., Shen, A., Boyle, L., Kunich, J., Pandey, K., Lemmon, M. J., Hermiston, T. W., Giedlin, M., McCormick, F. P., & Fattaey, A. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00060-0 · Cited by 191
Self-citation
Identification of novel mdm2 binding peptides by phage display.
Böttger, V., Böttger, A., Howard, S. F., Picksley, S. M., Chêne, P., Garcı́a-Echeverrı́a, C., Hochkeppel, H. K., & Lane, D. P. (1996) · PubMed · Cited by 182
Dual Inactivation of RB and p53 Pathways in RAS-Induced Melanomas
Bardeesy, N., Bastian, B. C., Hezel, A., Pinkel, D., DePinho, R. A., & Chin, L. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.6.2144-2153.2001 · Cited by 166
How do small GTPase signal transduction pathways regulate cell cycle entry?
Marshall, C. (1999) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(99)00044-7 · Cited by 161
Complexities in the development of cyclin-dependent kinase inhibitor drugs
Sausville, E. A. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02308-0 · Cited by 159
Therapeutic exploitation of the p53 pathway
Lane, D. P., & Laı́n, S. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02309-2 · Cited by 127
Modeling mutations in the G1 arrest pathway in human gliomas: overexpression of CDK4 but not loss of INK4a–ARF induces hyperploidy in cultured mouse astrocytesPreprint
Holland, E. C., Hively, W. P., Gallo, V., & VARMUS, H. E. (1998) · Genes & Development · doi:10.1101/gad.12.23.3644 · Cited by 124
E2F transcriptional repressor complexes are critical downstream targets of p19ARF/p53-induced proliferative arrest
Rowland, B. D., Denissov, S. G., Douma, S., Stunnenberg, H. G., Bernards, R., & Peeper, D. S. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00085-5 · Cited by 120
Loss of the ARF tumor suppressor reverses premature replicative arrest but not radiation hypersensitivity arising from disabled atm function.
Kamijo, T., van de Kamp, E. H., Chong, M. J., Zindy, F., Diehl, J. A., Sherr, C. J., & McKinnon, P. J. (1999) · PubMed · Cited by 117
Self-citation
ErbB2/Neu-Induced, Cyclin D1-Dependent Transformation Is Accelerated in p27-Haploinsufficient Mammary Epithelial Cells but Impaired in p27-Null Cells
Muraoka, R. S., Lenferink, A. E. G., Law, B. K., Hamilton, E., Brantley, D. M., Roebuck, L. R., & Arteaga, C. L. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.7.2204-2219.2002 · Cited by 116
Cell Cycle and Biochemical Effects of PD 0183812
Fry, D. W., Bedford, D. C., Harvey, P. H., Fritsch, A., Keller, P. R., Wu, Z., Dobrusin, E. M., Leopold, W. R., Fattaey, A., & Garrett, M. D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008867200 · Cited by 112
E2F1 Induces Phosphorylation of p53 That Is Coincident with p53 Accumulation and Apoptosis
Rogoff, H. A., Pickering, M., Debatis, M. E., Jones, S. N., & Kowalik, T. F. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.15.5308-5318.2002 · Cited by 111
Differential effects of p19 Arf and p16 Ink4a loss on senescence of murine bone marrow-derived preB cells and macrophages
Randle, D. H., Zindy, F., Sherr, C. J., & Roussel, M. F. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171217498 · Cited by 108
Self-citation
TUMOR SUPPRESSOR GENE MUTATIONS IN MICE
Jacks, T. (1996) · Annual Review of Genetics · doi:10.1146/annurev.genet.30.1.603 · Cited by 105
Differential requirement for p19ARF in the p53-dependent arrest induced by DNA damage, microtubule disruption, and ribonucleotide depletion
Khan, S. H., Moritsugu, J., & Wahl, G. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3266 · Cited by 103
Selective In Vivo and In Vitro Effects of a Small Molecule Inhibitor of Cyclin-Dependent Kinase 4
Soni, R., O'Reilly, T., Furet, P., Muller, L., Stephan, C., Zumstein-Mecker, S., Fretz, H., Fabbro, D., & Chaudhuri, B. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.6.436 · Cited by 98
Cyclin‐dependent kinase inhibitors for treating cancer
Toogood, P. L. (2001) · Medicinal Research Reviews · doi:10.1002/med.1021 · Cited by 94
Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention
Herrera, R., & Sebolt–Leopold, J. S. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02307-9 · Cited by 93
Suppression of the p53- or pRB-mediated G1 checkpoint is required for E2F-induced S-phase entry
Lomazzi, M., Moroni, M. C., Jensen, M. R., Frittoli, E., & Helin, K. (2002) · Nature Genetics · doi:10.1038/ng891 · Cited by 85
p19ARF Is Dispensable for Oncogenic Stress-Induced p53-Mediated Apoptosis and Tumor Suppression In Vivo
Tolbert, D., Lu, X., Yin, C., Tantama, M., & Dyke, T. V. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.1.370-377.2002 · Cited by 85
ARF Differentially Modulates Apoptosis Induced by E2F1 and Myc
Russell, J. L., Powers, J. T., Rounbehler, R. J., Rogers, P. M., Conti, C. J., & Johnson, D. G. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.5.1360-1368.2002 · Cited by 72
ARF Is Not Required for Apoptosis in Rb Mutant Mouse Embryos
Tsai, K. Y., MacPherson, D. P., Rubinson, D. A., Crowley, D. G., & Jacks, T. (2002) · Current Biology · doi:10.1016/s0960-9822(01)00659-5 · Cited by 63
Prognostic implications of expression of the cell cycle inhibitor protein p27Kip1
Cariou, S., Catzavelos, C., & Slingerland, J. M. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1006154900130 · Cited by 51
Rate-limiting effects of Cyclin D1 in transformation by ErbB2 predicts synergy between herceptin and flavopiridol.
Nahta, R., Iglehart, J. D., Kempkes, B., & Schmidt, E. V. (2002) · PubMed · Cited by 48
The alternative reading frame tumor suppressor inhibits growth through p21-dependent and p21-independent pathways.
Modestou, M., Puig-Antich, V., Korgaonkar, C. K., Eapen, A. K., & Quelle, D. E. (2001) · PubMed · Cited by 44
Does Detection of Circulating ONYX-015 Genome by Polymerase Chain Reaction Indicate Vector Replication?
Yver, A., Nemunaitis, J. J., & Cunningham, C. C. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.12.3155 · Cited by 7

Sorted by citations

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Cellular senescence: when bad things happen to good cells
Campisi, J., & d'Adda di Fagagna, F. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2233 · Cited by 4,441
Cell-cycle checkpoints and cancer
Kastan, M. B., & Bartek, J. (2004) · Nature · doi:10.1038/nature03097 · Cited by 2,836
Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors
Campisi, J. (2005) · Cell · doi:10.1016/j.cell.2005.02.003 · Cited by 2,379
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C., et al. (2007) · Genes & Development · doi:10.1101/gad.1596707 · Cited by 2,316

See all 1,690

Authors: Sherr, C. J., & McCormick, F.
Affiliations: St. Jude Children's Research Hospital (US)
University of California, San Francisco (US)
Corresponding author: Sherr, Charles J
ORCID: Sherr, Charles J
McCormick, Frank
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2002-08
Volume: 2
Issue: 2
Pages: 103-112
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/s1535-6108(02)00102-2
OpenAlex: W1992708996
Cited by: 1,690
References: 122
Citations by year: 2026: 31 · 2025: 40 · 2024: 36 · 2023: 60 · 2022: 56 · 2021: 62 · 2020: 62 · 2019: 67 · 2018: 75 · 2017: 67 · 2016: 60 · 2015: 71 · 2014: 88 · 2013: 81 · 2012: 90
FWCI: 7.67
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 4003 d)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords: retinoblastoma protein, p53, tumor suppressor, malignant transformation, signaling pathways, cancer etiology, tumor-specific therapy, oncogenic transformation
MeSH terms: Cell Cycle, DNA-Binding Proteins, Humans, Neoplasms, Transcription Factors, Signal Transduction, Tumor Suppressor Protein p53, Retinoblastoma Protein, Apoptosis, Cell Cycle Proteins, Cyclin-Dependent Kinase Inhibitor p16, E2F Transcription Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The RB and p53 pathways in cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks